CBS 2019
CBSMD教育中心
中 文

文献导读

Abstract

Recommended Article

可穿戴复律除颤仪 & 心源性猝死 直接PCI患者经基因型指导的口服P2Y12抑制剂策略选择 腔内影像学与负性重构 慢性血栓栓塞性肺动脉高压最新研究进展 PCI术后计划外再入院原因及应对策略 基因型指导口服P2Y12抑制剂策略 Galectin-3对心肌梗死后死亡与心衰的预测价值 支持低内皮剪切力在动脉粥样硬化形成扮演重要角色的最新证据

Original Research

JOURNAL:CBSMD Article Link

紫杉醇涂层球囊的最新研究进展

CBSMD

Pre-reading

支架内再狭窄仍是个临床难题,紫杉醇涂层球囊(Paclitaxel-coated balloons,PCBs)不失为一种替代方案。以下为PCBs的最新研究证据:


2019年1月新鲜出炉的Clinical and angiographic outcomes of coronary dissection after paclitaxel-coated balloon angioplasty for small vessel coronary artery disease纳入了单中心 2.8mm的小冠脉血管病变,试图解释PCB即可经造影明确的冠脉夹层的发生机制及分型,并开展了术后长于6个月的临床随访,以进一步观察冠脉夹层的进展。


Optical Coherence Tomography Predictors for Recurrent Restenosis After Paclitaxel-Coated Balloon Angioplasty for Drug-Eluting Stent Restenosis”介绍了PCB-Angioplasty治疗DES-ISR后复发再狭窄的OCT影像学发现,6个月后发生复发再狭窄病变处的组织异质性更高,再狭窄病变处的最小官腔、支架面积、支架膨胀程度等指标显著不足。


Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study”比较了3年PEB和DES在治疗BMS-ISR的长期疗效。


德国亚琛Schröder等回顾性完成了两种PCB术后一年MACE的比较分析“Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons采用单中心、非随机设计回顾性获取了单中心两种PCBs一年的MACE事概率(15.0 and 15.8% (P=0.879) for the BTHC-PCB and iopromide-based PCB groups)和1TLR、心梗、心源性死事件概率(分别为9.6 versus 11.8%, P=0.622; 5.3 versus 3.9%, P=0.640; and 5.3 versus 3.9%, P=0.640)。


Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 trial”比较了PCB两种药用辅料BTHC-PCB (n=127) iopromide-PCBn=137)置入6-8个月随访造影终点和1年临床终点。


Therapeutic efficacy of paclitaxel-coated balloon for de novo coronary lesions with diameters larger than 2.8 mm前瞻性地对以2.8mm为血管直径为分组阈值,在238例原发病变中评价紫杉醇涂层球囊的安全性和有效性。